Episodic (Viral) Wheeze vs. Multiple Trigger Wheeze

A Clinically Oriented Review for the Practicing Pediatrician

Based on Nelson Textbook of Pediatrics (21st ed.) | Kendig’s Disorders of the Respiratory Tract in Children (9th ed.) | AAP & IAP-NAPCON Official Resources

1. Introduction

Wheezing in preschool children (0–5 years) is one of the most common reasons for pediatric consultation and hospital admission worldwide. It is now well established that ‘preschool wheeze’ is not a single disease but a heterogeneous group of phenotypes with distinct pathophysiology, natural history, and responses to therapy. The two most clinically useful and validated phenotypes—recognized in both the Nelson Textbook of Pediatrics and major international guidelines—are:

• Episodic (Viral) Wheeze (EVW): wheezing episodes triggered exclusively by viral respiratory infections, with complete resolution between episodes.
• Multiple Trigger Wheeze (MTW): wheezing triggered by multiple stimuli including viruses, aeroallergens, exercise, cold air, tobacco smoke, and emotional stimuli, with symptoms also occurring between discrete episodes.

This classification, initially proposed by Brand et al. and incorporated into the PRACTALL Consensus Report (2008) of the European Academy of Allergy and Clinical Immunology (EAACI) and the American Academy of Allergy, Asthma and Immunology (AAAAI), is now endorsed by the American Academy of Pediatrics (AAP) and the Indian Academy of Pediatrics (IAP) / National Asthma Consensus Group (NACG).

2. Epidemiology

According to Nelson Textbook of Pediatrics (21st edition, Chapter 169: Wheezing in Infants and Children), approximately 30–40% of all children will experience at least one wheezing episode in the first three years of life, yet fewer than one-third of these will develop persistent asthma. Data from the Tucson Children’s Respiratory Study (TCRS), cited prominently in Nelson, delineates three early wheezing trajectories:

• Transient early wheezers: viral-triggered, remit by age 6; low atopic burden.
• Non-atopic wheezers (EVW phenotype): episode-only wheeze; best aligned with EVW.
• IgE-associated persistent wheezers (MTW/Asthma phenotype): atopic sensitization, family history, persistent into school age.

The IAP NAPCON 2019 Consensus Statement on Childhood Asthma notes that in South Asian children, including India and Nepal, the prevalence of preschool wheeze is significant, often complicated by high pollution exposure and early sensitization to house dust mite and cockroach allergens, features that shift the phenotype toward MTW.

3. Pathophysiology

3.1 Episodic (Viral) Wheeze

As described in Nelson (Chapter 169) and Kendig’s Disorders of the Respiratory Tract in Children (9th edition, Chapter 38), EVW is predominantly mediated by:

• Rhinovirus (RV) and respiratory syncytial virus (RSV) — the principal triggers in children <3 years.
• Neutrophilic airway inflammation: transient bronchial inflammation during the acute episode, with restoration of normal airway architecture between episodes. Unlike classical asthma, eosinophilic infiltration is typically absent or minimal.
• Small airway mechanics: infants have a high ratio of airway resistance due to anatomically smaller caliber airways, making them more susceptible to luminal obstruction from viral-induced mucosal edema and secretions.
• Immune dysregulation: reduced interferon-γ (IFN-γ) and impaired Th1 responses to RV have been demonstrated, contributing to prolonged viral shedding and exaggerated bronchospasm.
• No persistent structural remodeling: between episodes, lung function is typically normal and there is no evidence of airway remodeling or eosinophilic inflammation.

3.2 Multiple Trigger Wheeze

MTW pathophysiology, as detailed in both Nelson and Kendig’s, resembles that of classic atopic asthma:

• Eosinophilic airway inflammation: persistent even during asymptomatic intervals, with elevated fractional exhaled nitric oxide (FeNO).
• Th2-skewed immune response: elevated IgE, IL-4, IL-5, IL-13; mast cell and eosinophil activation with allergen exposure.
• Airway hyperresponsiveness (AHR): demonstrable on methacholine or exercise challenge, and persisting between symptomatic episodes.
• Early sensitization: specific IgE to house dust mite (Dermatophagoides pteronyssinus), cockroach, Alternaria, or other regional allergens is frequently demonstrable by age 2–3 years.
• Structural remodeling: subepithelial fibrosis and smooth muscle hypertrophy develop over time if left inadequately treated.

4. Clinical Features and Diagnosis

4.1 History

Nelson (21st ed., Chapter 169) and AAP Clinical Practice Guidelines for Asthma (2020 Update) recommend a detailed history focusing on:

• Trigger identification: exclusive viral triggers (EVW) vs. multiple triggers including allergens, exercise, cold air, irritants (MTW).
• Inter-episodic symptoms: nocturnal cough, exercise-induced wheeze, or persistent cough between viral episodes strongly suggests MTW.
• Atopic comorbidities: personal history of eczema, allergic rhinitis; food allergy.
• Family history: parental asthma/atopy increases the Asthma Predictive Index (API) score, supporting MTW/asthma phenotype.
• Environmental history: tobacco smoke exposure, cooking fuel, pet ownership, damp housing — relevant especially per IAP guidelines for South Asian settings.

4.2 Asthma Predictive Index (API)

The modified API (mAPI), described in Nelson and endorsed by the AAP, is a validated tool to identify preschool wheezers likely to develop persistent asthma (MTW phenotype). A positive mAPI in a child with ≥3 wheezing episodes in the past year has a positive predictive value of ~80% for asthma at school age.

Major criteria: (1) Parental asthma; (2) Physician-diagnosed atopic dermatitis; (3) Aeroallergen sensitization.

Minor criteria: (1) Food allergen sensitization; (2) ≥4% peripheral eosinophilia; (3) Wheezing apart from colds.

A positive API (1 major OR 2 minor) in a high-frequency wheezer predicts MTW/asthma phenotype and guides more aggressive preventive therapy.

4.3 Physical Examination

Physical findings are largely similar during acute episodes in both phenotypes. However, clinicians should look for:

• Stigmata of atopy (eczema, infraorbital shiners, allergic salute, nasal polyps) — favoring MTW.
• Digital clubbing, persistent hyperinflation, failure to thrive — suggest alternative diagnoses (cystic fibrosis, primary ciliary dyskinesia, structural airway anomalies).
• Normal examination between episodes — expected in EVW; persistent wheeze or hyperinflation between episodes raises suspicion for MTW or alternative pathology.

4.4 Investigations

Kendig’s (9th ed., Chapter 38) and AAP Guidelines recommend the following investigations based on clinical context:

• Spirometry (≥5–6 years): reversible airflow obstruction (post-bronchodilator FEV1 improvement ≥12%) supports MTW/asthma; may be normal in EVW.
• Skin prick testing / Specific IgE: aeroallergen sensitization supports MTW phenotype; recommended in children with positive mAPI or recurrent MTW.
• Complete blood count: peripheral eosinophilia (≥4%) is a minor API criterion.
• Chest radiograph: to exclude structural anomalies, foreign body, or consolidation; not routinely needed for wheeze per AAP guidelines.
• FeNO measurement: elevated (>25 ppb) supports eosinophilic airway inflammation (MTW/asthma); not universally available but referenced in Nelson and Kendig’s.
• Bronchoscopy / BAL: reserved for diagnostically challenging cases; mentioned in Kendig’s for evaluation of structural/anatomic causes of wheeze.

5. Comparative Overview: EVW vs. MTW

Table 1 summarizes the key distinguishing features of the two preschool wheeze phenotypes.

Table 1. Episodic Viral Wheeze vs. Multiple Trigger Wheeze — Comparative Features

Feature	Episodic Viral Wheeze (EVW)	Multiple Trigger Wheeze (MTW)
Trigger pattern	Only viral URTIs; symptom-free between episodes	Viral + aeroallergens, exercise, cold air, smoke; persistent/interval symptoms
Typical age	Predominantly <3 years (preschool)	Any preschool age; more likely to persist into school age
Atopic features	Usually absent; non-atopic phenotype	Often present: eczema, allergic rhinitis, sensitization
Family history	Less prominent	Positive asthma/atopy family history common
Lung function (interval)	Normal between episodes	May show airflow limitation between episodes
Airway inflammation	Predominantly neutrophilic; transient	Eosinophilic; chronic even between episodes
Response to ICS	Limited/inconsistent benefit in trials	Better response; ICS often indicated
LABA benefit	Not established	May be considered as add-on (age-appropriate)
Montelukast	Modest benefit in some studies (episodic use)	Regular use may help; part of step-up therapy
Prognosis	Many remit by school age	Higher risk of persisting asthma

Source: Nelson Textbook of Pediatrics 21e (Chapter 169); Kendig’s 9e (Chapter 38); Brand et al., PRACTALL Consensus Report 2008; AAP; IAP-NAPCON 2019.

6. Differential Diagnosis

Both Nelson and Kendig’s emphasize that preschool wheeze is not always asthma or EVW/MTW. The following should be actively excluded:

• Cystic Fibrosis (CF): failure to thrive, steatorrhoea, digital clubbing, neonatal jaundice, positive sweat chloride test.
• Primary Ciliary Dyskinesia (PCD): daily productive cough from birth, situs inversus (in ~50%), bronchiectasis on imaging.
• Tracheobronchomalacia: monophasic wheeze from birth, worsens with agitation/feeding, may improve in prone position.
• Foreign body aspiration: sudden onset, unilateral wheeze, history of aspiration event.
• Vascular ring/sling: persistent stridor/wheeze, dysphagia, abnormal barium swallow or CT angiography.
• Gastroesophageal Reflux Disease (GERD): feeding-associated symptoms, laryngeal findings; however, causality with wheeze is debated.
• Immune deficiency: recurrent infections beyond wheeze, failure to thrive, lymphopenia.
• Congenital heart disease: cardiac murmur, differential cyanosis, abnormal echocardiogram.

7. Management

7.1 Acute Episode Management (Both Phenotypes)

Per AAP Clinical Practice Guidelines (2020) and Nelson (Chapter 169), acute management is phenotype-independent and follows standard bronchodilator therapy:

• Short-Acting Beta-2 Agonists (SABA): salbutamol (albuterol) 2.5–5 mg via nebulizer, or 2–4 puffs via spacer and face mask every 20 minutes for 3 doses in severe episodes. First-line therapy for all preschool wheeze.
• Ipratropium bromide: may be added for moderate-to-severe exacerbations; reduces hospitalization when combined with salbutamol.
• Systemic corticosteroids: oral prednisolone (1–2 mg/kg/day, max 40 mg, for 3–5 days) for moderate-to-severe exacerbations. Per the AAP, short courses do not significantly affect adrenal function or growth in children.
• Supplemental oxygen: titrate to maintain SpO2 ≥94% (AAP target); SpO2 ≥95% per IAP-NAPCON 2019.
• Hospitalization criteria: SpO2 <92% on room air, severe respiratory distress (HR >60/min in infants), inability to maintain oral feeds, poor response to initial bronchodilators.

7.2 Preventive/Controller Therapy

This is where the phenotype distinction critically guides management:

7.2.1 Episodic (Viral) Wheeze

Per Nelson, Kendig’s, and AAP Guidelines:

• Continuous ICS: NOT routinely recommended for EVW. Multiple RCTs (including the PEAK and MIST trials cited in Nelson) show no significant reduction in episode frequency or severity with continuous low-dose ICS in non-atopic preschool wheezers.
• Intermittent/episodic ICS: high-dose ICS at the onset of a viral URTI (e.g., budesonide 400 mcg/day or fluticasone 200 mcg/day for 7–10 days) may reduce episode severity in selected children, though evidence remains inconsistent across trials.
• Montelukast: episodic use at onset of wheeze shows modest benefit in some studies (Bisgaard et al., NEJM, cited in Nelson); may be considered for children with 3 or more episodes per year.
• Bronchodilator reliever therapy: salbutamol as needed during episodes. Continuous reliever use between episodes is not indicated in pure EVW.
• Avoidance: passive smoking cessation, hand hygiene, daycare modifications to reduce viral exposure.

7.2.2 Multiple Trigger Wheeze

Per Nelson, Kendig’s, AAP (2020), and IAP-NAPCON (2019):

• Low-dose ICS: first-line preventer therapy. Budesonide 100–200 mcg/day or fluticasone propionate 100 mcg/day (BDP-equivalent). Initiate when diagnosis of MTW/persistent asthma is established.
• Montelukast: may be used as an alternative to ICS in mild MTW or as add-on therapy in moderate MTW. IAP-NAPCON recognizes its role given high house dust mite sensitization in the South Asian context.
• Medium-dose ICS: step up to 200–400 mcg/day (budesonide equivalent) if low-dose ICS fails to achieve symptom control after 6–8 weeks.
• LABA addition: for children ≥5 years with inadequate control on medium-dose ICS, salmeterol or formoterol can be added. Not approved or recommended for children <4 years as monotherapy.
• Allergen avoidance: mattress/pillow encasements, HEPA filtration, pet removal — strongly recommended by AAP and IAP for sensitized children with MTW.
• Allergen Immunotherapy (AIT): subcutaneous or sublingual AIT for house dust mite-sensitized children with MTW/asthma is recommended in international guidelines and endorsed in IAP-NAPCON for appropriate candidates ≥5 years.
• Omalizumab: anti-IgE therapy; approved for moderate-to-severe persistent allergic asthma in children ≥6 years; referenced in Nelson and AAP guidelines for refractory MTW/asthma with high IgE and allergen sensitization.

7.3 Step-Therapy Summary

Table 2. Stepwise Treatment Approach for EVW and MTW

Step	EVW Management	MTW Management
Acute	SABA (salbutamol) via spacer/nebulizer; oral prednisolone for moderate-severe	SABA; oral/systemic corticosteroids; consider early ICS step-up
Preventer	Not routinely indicated; trial ICS only if frequent/severe episodes (≥3/year)	Low-dose ICS (e.g., budesonide 100–200 mcg/day) as first-line preventer
Step-up	Episodic ICS at onset of URTI (intermittent therapy); montelukast episodic use	Increase ICS dose; add montelukast or LABA (≥5 yr); consider specialist referral
Monitoring	Symptom diary; reassess trigger pattern at each visit	Spirometry (if age-appropriate); allergy testing; adherence review

Adapted from: Nelson Textbook of Pediatrics 21e; AAP Clinical Practice Guidelines (2020); IAP-NAPCON Consensus Statement 2019.

7.4 Delivery Devices

Per AAP and IAP-NAPCON recommendations:

• 0–3 years: pMDI + valved spacer with face mask (preferred); nebulizer is an acceptable alternative.
• 3–5 years: pMDI + valved spacer with mouthpiece; child should be able to maintain a seal.
• ≥6 years: pMDI + spacer or dry powder inhaler (DPI); spirometry-guided device selection.

Nebulizers are not superior to pMDI+spacer for acute bronchodilation and carry infection transmission risk in healthcare settings. Both AAP and IAP recommend prioritizing spacer-based delivery.

8. Monitoring and Follow-Up

Nelson, AAP (2020 Expert Panel Report 3 Update), and IAP-NAPCON recommend the following monitoring framework:

1. Review diagnosis every 3–6 months: re-evaluate whether phenotype has shifted from EVW to MTW as the child grows.
2. Assess symptom control using validated tools: \Childhood Asthma Control Test (C-ACT) for children ≥4 years; parent-report tools for younger children.
3. Spirometry when developmentally feasible (≥5 years): monitor FEV1, FVC, and FEV1/FVC ratio at each visit.
4. Reassess trigger profile at each visit: new aeroallergen sensitization, school exposures, change in environment.
5. Monitor growth: height and weight percentile; ICS at low doses does not significantly affect final adult height per Nelson; monitor with medium-to-high doses.
6. Adherence and inhaler technique: check at every visit; poor technique is the most common cause of apparent treatment failure per AAP.
7. Consider step-down: if well-controlled for ≥3 months, cautiously step down therapy, reassessing trigger pattern.

9. Prognosis and Natural History

The TCRS and birth cohort studies cited in Nelson provide the most robust data on prognosis:

• EVW (Transient wheeze): ~60% of preschool wheezers remit by 6 years of age. These children, corresponding to the EVW phenotype, generally have normal lung function at school age. The absence of atopic sensitization, normal lung function between episodes, and non-positive API predict favorable outcome.
• MTW (Persistent/Asthma phenotype): ~40% of preschool wheezers continue to wheeze at school age. Risk factors for persistence include: positive mAPI, maternal asthma, early sensitization to aeroallergens, frequent episodes in the first 3 years, male sex, and exposure to high-dose indoor allergens.
• Lung function trajectory: Lung function deficits, if present at age 6 years in the MTW group, tend to track into adult life and are associated with increased risk of COPD in adulthood (“early origins of adult lung disease” concept, cited in Nelson and Kendig’s).
• South Asian context (IAP): earlier sensitization to perennial allergens (HDM, cockroach), higher pollution burden, and lower vitamin D levels may confer worse outcomes in the MTW phenotype in Indian children, as noted in IAP-NAPCON 2019.

10. Special Clinical Situations

10.1 The “Overlap” Child

Many children present with features of both EVW and MTW, especially between ages 2–4 years. Nelson recommends using the mAPI as a practical decision aid in such cases. If the mAPI is positive, treat as MTW (initiate regular ICS); if negative, manage as EVW (episodic/as-needed therapy).

10.2 Very Young Infants (<12 months)

Wheezing in infants under 12 months is most commonly due to bronchiolitis (RSV) and should not be classified as EVW or MTW. Per AAP Clinical Practice Guideline for the Diagnosis, Management, and Prevention of Bronchiolitis (2014, reaffirmed 2020), bronchodilators are not recommended for infants with bronchiolitis. ICS and systemic steroids are similarly not recommended in this age group for acute bronchiolitis.

10.3 COVID-19 and Respiratory Viruses

The AAP has issued guidance noting that SARS-CoV-2 infection in young children may trigger wheezing episodes similar to other viral URTI triggers in EVW. Standard asthma action plans should include COVID-19 as a potential EVW trigger; ICS should not be stopped during COVID-19 illness in MTW/asthma patients.

10.4 Vaccination

Both AAP and IAP recommend annual influenza vaccination for all children with recurrent wheezing (EVW or MTW), as influenza is a significant trigger for severe exacerbations. Pneumococcal vaccination per national immunization schedules is also recommended.

11. Parent and Caregiver Education

AAP and IAP emphasize that education is a cornerstone of management:

• Provide written Asthma Action Plan (AAP template available at healthychildren.org) for all children with recurrent wheeze.
• Educate on symptom recognition: early signs of exacerbation (nocturnal cough, reduced exercise tolerance, increased rescue inhaler use).
• Inhaler technique training at every visit; video demonstrations and teach-back methods are recommended by AAP.
• Environmental control counseling: tobacco smoke, allergen avoidance, mold reduction, pet dander management.
• Address caregiver anxiety: explain phenotype, natural history, and that EVW does not inevitably become asthma.
• Emphasize adherence to preventive therapy in MTW: parents often reduce ICS doses prematurely when symptoms improve.

12. Key Clinical Takeaways

• Phenotype matters: Distinguish EVW from MTW at every clinical encounter; this distinction drives preventive therapy decisions.
• mAPI guides therapy: A positive mAPI in a high-frequency preschool wheezer indicates MTW/asthma phenotype and justifies early ICS therapy.
• ICS is not universal: Continuous ICS is not recommended for pure EVW; reserve for MTW or EVW with frequent/severe episodes.
• Trigger profile shapes management: Allergen sensitization testing is indicated when MTW is suspected; AIT may be indicated in sensitized children ≥5 years.
• Phenotypes are dynamic: Reassess at every visit; EVW may evolve to MTW as atopic sensitization develops.
• Guideline resources: Use AAP (healthychildren.org, aappublications.org) and IAP-NAPCON (iapindia.org) official resources for updated local guidance.
• Exclude mimics: Always consider structural, infectious, and congenital causes of recurrent wheeze, especially in children <12 months or with atypical features.

References

Primary Textbook References:

1. Kliegman RM, St. Geme JW, Blum NJ, et al. Nelson Textbook of Pediatrics, 21st Edition. Philadelphia: Elsevier; 2020. Chapter 169: Wheezing in Infants and Young Children; Chapter 170: Asthma.
2. Wilmott RW, Deterding R, Li A, et al. Kendig’s Disorders of the Respiratory Tract in Children, 9th Edition. Philadelphia: Elsevier; 2019. Chapter 38: Wheezing in Infancy and Early Childhood; Chapter 39: Asthma in the Pediatric Patient.

AAP Official Resources:

1. American Academy of Pediatrics. Clinical Practice Guideline for the Diagnosis, Evaluation, and Management of Childhood Asthma. Pediatrics. 2020;145(3):e20193432. Available at: https://publications.aap.org
2. American Academy of Pediatrics. Clinical Practice Guideline: The Diagnosis, Management, and Prevention of Bronchiolitis. Pediatrics. 2014;134(5):e1474-e1502. Reaffirmed 2020. Available at: https://publications.aap.org
3. American Academy of Pediatrics. Asthma Action Plan templates and parent education resources. HealthyChildren.org. Available at: https://www.healthychildren.org

IAP Official Resources:

• Indian Academy of Pediatrics, National Asthma Consensus Group (NAPCON). IAP-NAPCON Consensus Statement on Childhood Asthma 2019. Indian Pediatrics. 2020;57(1):42–58. Available at: https://www.indianpediatrics.net
• Indian Academy of Pediatrics. IAP Standard Treatment Guidelines: Bronchial Asthma in Children. 2022. Available at: https://www.iapindia.org

Landmark Studies and Consensus Documents (cited in Nelson/Kendig’s):

• Brand PL, Baraldi E, Bisgaard H, et al. Definition, assessment and treatment of wheezing disorders in preschool children: an evidence-based approach. European Respiratory Journal. 2008;32(4):1096–1110. [PRACTALL Consensus Report, cited in Nelson 21e and Kendig’s 9e]
• Martinez FD, Wright AL, Taussig LM, et al. Asthma and wheezing in the first six years of life: The Group Health Medical Associates. New England Journal of Medicine. 1995;332(3):133–138. [Tucson Children’s Respiratory Study, cited in Nelson 21e]
• National Asthma Education and Prevention Program (NAEPP). Expert Panel Report 3 (EPR-3): Guidelines for the Diagnosis and Management of Asthma. National Heart, Lung, and Blood Institute (NHLBI). 2007 (Updated 2020). Available at: https://www.nhlbi.nih.gov
• Global Initiative for Asthma (GINA). Difficult-to-Treat and Severe Asthma in Adolescent and Adult Patients: A GINA Pocket Guide. 2023. [Referenced in Nelson and Kendig’s for management framework]